Eli Lilly's Weight Loss Pill Foundayo Has Over 20,000 Users in First Few Weeks
Eli Lilly's new weight loss pill, Foundayo, has attracted over 20,000 users in its first few weeks on the market, according to CEO Dave Ricks. The FDA approved Foundayo earlier this month, making it the second oral GLP-1 drug after Novo Nordisk's Wegovy. Investors are closely monitoring prescription data to gauge the drug's market performance.
Topics: Eli Lilly FDA approval GLP-1 drug pharmaceuticals weight loss drug